No, Dupixent (dupilumab) does not cause hyponatremia
Hyponatremia is not a recognized adverse effect of dupilumab based on FDA labeling, clinical guidelines, or published safety data. After reviewing the FDA prescribing information and extensive safety literature covering up to 5 years of treatment experience, hyponatremia does not appear among the documented adverse events associated with this medication 1.
Known Adverse Effects of Dupixent
The most common and clinically relevant side effects documented in the FDA label and clinical practice include 1:
Most Frequent (>5% incidence):
- Ocular complications (6-26% in real-world data): conjunctivitis, dry eyes, eye pain, blurred vision 2
- Injection site reactions
- Upper respiratory tract infections
- Nasopharyngitis
- Herpes simplex infections (cold sores)
Less Common but Important:
- Head and neck dermatitis (19.5% in real-world cohorts) 3
- Eosinophilia - can be transient and usually clinically insignificant 4, 5
- Allergic reactions (rare but potentially severe)
- Joint pain and arthralgia (may require hospitalization in rare cases) 1
Laboratory Parameters
Long-term safety data spanning up to 5 years shows no clinically meaningful changes in serum chemistry parameters, including electrolytes 6. The only laboratory abnormality mentioned in one case report was hypokalemia (low potassium), not hyponatremia, occurring in the context of gastrointestinal symptoms 7.
Clinical Implication
If a patient on dupilumab presents with hyponatremia, look for alternative causes rather than attributing it to the medication. The drug does not require routine laboratory monitoring for electrolyte disturbances 6.